The use of cationic nanogels to deliver proteins to myeloma cells and primary T lymphocytes that poorly express heparan sulfate

Biomaterials

Volumn 32, Issue 25, 2011, Pages 5900-5905

  Watanabe, Kozo ^a,b   Tsuchiya, Yumiko ^a   Kawaguchi, Yoshinori ^a   Sawada, Shin ichi ^a   Ayame, Hirohito ^a   Akiyoshi, Kazunari ^a,c   Tsubata, Takeshi ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Cationic cholesteryl group bearing pullulans; Hydrogel; Lymphocyte; Macropinocytosis; Nanoparticle; Protein delivery

Indexed keywords

ANTI-APOPTOTIC PROTEIN; APOPTOSIS; CANCER THERAPY; FUNCTIONAL REGULATION; FUSION PROTEINS; HEPARAN SULFATES; INTRACELLULAR DELIVERY; LYMPHOCYTE; MACROPINOCYTOSIS; METASTATIC TUMORS; MYELOMA CELL; NANO-SIZE; NANOGELS; PROTEIN DELIVERY; PROTEIN TRANSDUCTION DOMAINS; PULLULANS; T LYMPHOCYTES; TARGET CELLS;

BEARINGS (STRUCTURAL); CELL DEATH; HYDROGELS; NANOSTRUCTURED MATERIALS;

PROTEINS;

HEPARAN SULFATE; HYBRID PROTEIN; NANOPARTICLE; PROTEIN BCL XL; PULLULAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HYDROGEL; MACROPINOCYTOSIS; MOUSE; MYELOMA CELL; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; CATIONS; CELL LINE, TUMOR; FLOW CYTOMETRY; HEPARITIN SULFATE; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; NANOSTRUCTURES; NANOTECHNOLOGY; T-LYMPHOCYTES;

EID: 79957907480     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.04.058     Document Type: Article

References (23)

1. Tyagi M., Rusnati M., Presta M., Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001, 276:3254-3261.
2. Suzuki T., Futaki S., Niwa M., Tanaka S., Ueda K., Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002, 277:2437-2443.
3. Fuchs S.M., Raines R.T. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004, 43:2438-2444.
4. Marty C., Meylan C., Schott H., Ballmer-Hofer K., Schwendener R.A. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol Life Sci 2004, 61:1785-1794.
5. Poon G.M., Gariepy J. Cell-surface proteoglycans as molecular portals for cationic peptide and polymer entry into cells. Biochem Soc Trans 2007, 35:788-793.
6. Nishi K., Saigo K. Cellular internalization of green fluorescent protein fused with herpes simplex virus protein VP22 via a lipid raft-mediated endocytic pathway independent of caveolae and Rho family GTPases but dependent on dynamin and Arf6. J Biol Chem 2007, 282:27503-27517.
7. Nakajima M., Irimura T., Di Ferrante D., Di Ferrante N., Nicolson G.L. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 1983, 220:611-613.
8. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999, 5:793-802.
9. Hulett M.D., Freeman C., Hamdorf B.J., Baker R.T., Harris M.J., Parish C.R. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 1999, 5:803-809.
10. Yang Y., Macleod V., Bendre M., Huang Y., Theus A.M., Miao H.Q., et al. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005, 105:1303-1309.
11. Ostrovsky O., Korostishevsky M., Levite I., Leiba M., Galski H., Vlodavsky I., et al. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 2007, 21:2296-2303.
12. Shafat I., Barak A.B., Postovsky S., Elhasid R., Ilan N., Vlodavsky I., et al. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 2007, 9:909-916.
13. Kelly T., Miao H.Q., Yang Y., Navarro E., Kussie P., Huang Y., et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 2003, 63:8749-8756.
14. Mahtouk K., Hose D., Raynaud P., Hundemer M., Jourdan M., Jourdan E., et al. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007, 109:4914-4923.
15. Zelphati O., Wang Y., Kitada S., Reed J.C., Felgner P.L., Corbeil J. Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem 2001, 276:35103-35110.
16. Dalkara D., Zuber G., Behr J.P. Intracytoplasmic delivery of anionic proteins. Mol Ther 2004, 9:964-969.
17. Morris M.C., Depollier J., Mery J., Heitz F., Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001, 19:1173-1176.
18. Ayame H., Morimoto N., Akiyoshi K. Self-assembled cationic nanogels for intracellular protein delivery. Bioconjug Chem 2008, 19:882-890.
19. Nochi T., Yuki Y., Takahashi H., Sawada S., Mejima M., Kohda T., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 2010, 9:572-578.
20. Kearney J.F., Radbruch A., Liesegang B., Rajewsky K. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 1979, 123:1548-1550.
21. Lundblad A., Steller R., Kabat E.A., Hirst J.W., Weigert M.G., Cohn M. Immunochemical studies on mouse myeloma proteins with specificity for dextran or for levan. Immunochemistry 1972, 9:535-544.
22. Akiyoshi K., Deguchi S., Moriguchi N., Yamaguchi S., Sunamoto J. Self-aggregates of hydrophobized polysaccharides in water. Formation and characteristics of nanoparticles. Macromolecules 1993, 26:3062-3068.
23. Kitamura T., Koshino Y., Shibata F., Oki T., Nakajima H., Nosaka T., et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003, 31:1007-1014.